Recent developments
Capacity and assets
In biopharma capacity, Merck’s $3 billion Elkton, Virginia facility advanced U.S. domestic manufacturing plans. WuXi Biologics’ sale agreement for its Leverkusen drug product plant to Terumo signaled portfolio realignment. Terumo’s acquisition of the Leverkusen plant adds European fill-finish capacity in vials and polymer syringes.
Quality and ESG
Operational quality remained central as three WuXi Biologics facilities gained TITCK GMP certification following inspection of mAb programs. Commercial and development scale was highlighted by WuXi Biologics’ 864-project portfolio and accelerated IND timelines. Sustainability credentials were reinforced with a third consecutive MSCI AAA ESG rating for WuXi Biologics.
Modalities and inputs
In nucleic acids, Mitsubishi Gas Chemical and Cirena’s Japan distribution framework for long-chain RNA, and Evonik’s collaboration with Ethris on an LNP platform, advanced delivery and CDMO options. Bioprocess inputs evolved with Evonik’s MaxiPure Polysorbate 80 for injectables, addressing formulation stability constraints. Cell and gene therapy manufacturing gained cross-border options via BBG Advanced Therapies and CELLforCURE’s transatlantic ATMP partnership.
Market and innovation
Market backdrop remained mixed as WACKER reported lower Q2 sales and EBITDA amid softer demand and utilization. Innovation linkages were underscored when Evonik honored Nobel laureate Ben Feringa, reflecting ongoing academia–industry engagement.